Welcome to DailyUpdates Infectious diseases - the R&D community's bulletin of breaking research, clinical trials and drug development news. This page will update each day. You have access for 1 more day(s). To receive DailyUpdates by e-mail register here


PubMed DailyUpdates: Breaking Scientific Publications for the Drug Discovery Community

DailyUpdates by e-mail - the publication tracker for the drug discovery community

Infectious diseases



If this icon appears after any of our listed articles, the author is able to provide reprints. Articles denoted by an Licensing Op. icon describe data relevant to licensing opportunities. The report icon, , links through to full analyses relating to pharmaceutical/market developments relating to this work

Today's journal articles

Bacterial Flagellin Stimulates Toll-Like Receptor 5-Dependent Defense against Vancomycin-Resistant Enterococcus Infection.

The inhibitor of cyclin - dependent kinases, olomoucine II, exhibits potent antiviral properties.

Effective siRNAs inhibit the replication of novel influenza A (H1N1) virus.

Do you need further information on any of the agents being evaluated in the trial(s) below?  Let us know...

New Clinical Trials

No clinical trials today

Previous Journal Entries

Immunogenicity and safety of different injection routes and schedules of IC41, a Hepatitis C virus (HCV) peptide vaccine.

Ritonavir protects against the development of atherosclerosis in APOE*3-Leiden mice.

Synthesis and the biological evaluation of arylnaphthalene lignans as anti - hepatitis B virus agents.

Carbonic anhydrase activators: Activation of the beta - carbonic anhydrases from the pathogenic fungi Candida albicans and Cryptococcus neoformans with amines and amino acids.

Interaction of antimicrobial peptide s-thanatin with lipopolysaccharide in vitro and in an experimental mouse model of septic shock caused by a multidrug-resistant clinical isolate of Escherichia coli.

Homology modeling, docking, and molecular dynamics reveal HR1039 as a potent inhibitor of 2009 A(H1N1) influenza neuraminidase.

FV - 100: the most potent and selective anti - varicella zoster virus agent reported to date.

An octahydro - cyclopenta[c]pyrrole series of inhibitors of the type 1 glycine transporter.

5-Benzylidenethiazolidin-4-ones as Multitarget Inhibitors of Bacterial Mur Ligases.

The development, optimization and validation of an assay for high throughput antiviral drug screening against Dengue virus.

CS-8958 (laninamivir prodrug), a long-acting neuraminidase inhibitor, shows superior anti-influenza virus activity after a single administration.

In vitro and in vivo Activities of the novel Anti-Cytomegalovirus Compound AIC246.

Genotypic/phenotypic patterns of HIV-1 integrase resistance to raltegravir.

Interleukin-4 inhibits an early phase in the HIV-1 life cycle in the human colorectal cell line HT-29.

Synthesis of triazolothiazolidinone derivatives of coumarin with antimicrobial activity.

Synthesis and antibacterial activity of benzyl - [3 - (benzylamino - methyl) - cyclohexylmethyl] - amine derivatives.

Intranasal vaccinations with the trans-sialidase antigen plus CpG adjuvant induce mucosal immunity protective against conjunctival T. cruzi challenges.

Synthesis, characterization and antibacterial activities of some new ferrocene - containing penems.

Synthesis and antimicrobial activities of novel 1,5 - diaryl pyrazoles.

Synthesis and antimicrobial activity of 2 - fluorophenyl - 4,6 - disubstituted [1,3,5]triazines.

Today's News Items

Optimer Pharmaceuticals Announces Positive Results from Second Fidaxomicin Phase 3 Study in Patients with Clostridium Difficile Infection

NOVAVAX Reports Additional Positive Data from its Trivalent Seasonal Influenza (VLP) Vaccine Clinical Study in Healthy Adults

Inovio Biomedical Cervical Cancer Therapeutic Vaccine Generates Dose-Related Immune Response in Clinical Trial

GeoVax Clinical Trial Update

Training Courses & Meetings

No events listed

Previous News Items

FDA ACCEPTS TOPICA’S LULICONAZOLE IND TO BEGIN CLINICAL TRIALS IN ONYCHOMYCOSIS

Romark Initiates Clinical Trial of Alinia for Treatment of Influenza